111 related articles for article (PubMed ID: 20170337)
1. Description and assessment of a model for GSK-3beta database virtual screening.
Ventimila N; Dupont PY; Laguerre M; Dessolin J
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):152-7. PubMed ID: 20170337
[TBL] [Abstract][Full Text] [Related]
2. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors.
Polgár T; Baki A; Szendrei GI; Keseru GM
J Med Chem; 2005 Dec; 48(25):7946-59. PubMed ID: 16335919
[TBL] [Abstract][Full Text] [Related]
3. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
[TBL] [Abstract][Full Text] [Related]
4. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
5. In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3β.
Bisignano P; Lambruschini C; Bicego M; Murino V; Favia AD; Cavalli A
J Chem Inf Model; 2012 Dec; 52(12):3233-44. PubMed ID: 23198830
[TBL] [Abstract][Full Text] [Related]
6. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
8. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
10. Novel GSK-3beta inhibitors from sequential virtual screening.
Kim HJ; Choo H; Cho YS; No KT; Pae AN
Bioorg Med Chem; 2008 Jan; 16(2):636-43. PubMed ID: 18006321
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel GSK-3β Inhibitors Using Pharmacophore and Virtual Screening Studies.
Balakrishnan N; Raj JS; Kandakatla N
Interdiscip Sci; 2016 Sep; 8(3):303-11. PubMed ID: 26298578
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Discovery of 1H-Indazole-3-carboxamides as a Novel Structural Class of Human GSK-3 Inhibitors.
Ombrato R; Cazzolla N; Mancini F; Mangano G
J Chem Inf Model; 2015 Dec; 55(12):2540-51. PubMed ID: 26600430
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
15. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening of glycogen synthase kinase 3β inhibitors: analysis of scoring functions applied to large true actives and decoy sets.
Osolodkin DI; Palyulin VA; Zefirov NS
Chem Biol Drug Des; 2011 Sep; 78(3):378-90. PubMed ID: 21679374
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
18. Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β.
Kitamura K; Tamura Y; Ueki T; Ogata K; Noda S; Himeno R; Chuman H
J Chem Inf Model; 2014 Jun; 54(6):1653-60. PubMed ID: 24884406
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
Khanfar MA; Hill RA; Kaddoumi A; El Sayed KA
J Med Chem; 2010 Dec; 53(24):8534-45. PubMed ID: 21082766
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development.
Slynko I; Scharfe M; Rumpf T; Eib J; Metzger E; Schüle R; Jung M; Sippl W
J Chem Inf Model; 2014 Jan; 54(1):138-50. PubMed ID: 24377786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
